CD73

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Friday, April 5, 2024
CDTX, Colorectal cancer, Drug, Adenosine, Patient, SAN, Tavarua, AACR, Therapy, Cancer, Pathology, CCR5, CD73, DFC, San Diego Convention Center, Oleclumab, Escape Room, Vaccine

SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced the company will deliver four poster presentations, including one late-breaking poster presentation, at this year’s American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 at the San Diego Convention Center in San Diego, California. The presentations highlight data on the company’s multispecific CD73/PD-1 drug Fc-conjugate (DFC), its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73.

Key Points: 
  • The presentations highlight data on the company’s multispecific CD73/PD-1 drug Fc-conjugate (DFC), its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73.
  • “Our Cloudbreak platform has quickly produced DFC candidates effective in preclinical studies across various cancers with specific disease targets.
  • This week, we are sharing data on our CCR5 DFC program for the first time, which has demonstrated robust efficacy as a monotherapy in mouse models of colorectal cancer.
  • Targeting CCR5 has the potential to improve response rates to immune checkpoint inhibitor therapies, which could have a greater impact for patients unresponsive to these current treatment options.

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

Retrieved on: 
Wednesday, February 21, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Cancer, PFS, PD, KIT, Toxicity, Anemia, Roche, Research and development, Security (finance), Part, Hypoxia, PD-1, Belzutifan, Safety, Income tax, Death, Access code, Administration, Exelixis, Webcast, Patient, Acceleration, TIGIT, Plasma, G&A, Pancreatic cancer, AXL, CD73, Pharmaceutical industry

Enrollment was discontinued for the Phase 3 study ARC-10 evaluating domvanalimab plus zimberelimab compared to pembrolizumab in first-line PD-L1-high NSCLC.

Key Points: 
  • Enrollment was discontinued for the Phase 3 study ARC-10 evaluating domvanalimab plus zimberelimab compared to pembrolizumab in first-line PD-L1-high NSCLC.
  • The companies also plan to initiate a Phase 2 trial to evaluate domvanalimab plus zimberelimab in a new disease setting.
  • Arcus will host a conference call and webcast today, February 21, at 2:00 PM PT / 5:00 PM ET to discuss its fourth-quarter and full-year 2023 financial results and pipeline updates.
  • To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com .

Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO

Retrieved on: 
Monday, February 12, 2024
SAN, European Commission, Committee, CDTX, Tavarua, Caspofungin, FDA, Standard of care, Fungemia, Civil service commission, Therapy, CHMP, Patient, DFC, IND, Immune system, CD73, Pharmaceutical industry

SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced receipt of an $11.14 million milestone payment from Mundipharma following the European approval of REZZAYO™ (rezafungin acetate), a novel, once-weekly echinocandin antifungal approved for the treatment of invasive candidiasis in adults.

Key Points: 
  • SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced receipt of an $11.14 million milestone payment from Mundipharma following the European approval of REZZAYO™ (rezafungin acetate), a novel, once-weekly echinocandin antifungal approved for the treatment of invasive candidiasis in adults.
  • The drug was previously approved by the United States Food and Drug Administration (FDA) for the treatment of candidemia and invasive candidiasis in patients with limited or no treatment options.
  • “The European approval of REZZAYO marks a significant milestone for patients who are in need of new treatment options for invasive candidiasis, and we look forward to seeing Mundipharma bring it to the EU market,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
  • Its lead oncology DFC, CBO421, is a potential best-in-class inhibitor of CD73, a validated target highly expressed on tumor cells.

Gilead and Arcus Announce Amended Collaboration and Equity Investment

Retrieved on: 
Monday, January 29, 2024
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Pancreatic cancer, Patient, Research, MD, Science, Partnership, Cancer, Lung cancer, NSCLC, CD73, Gilead Sciences, Safety, Gastrointestinal cancer, Doctor of Philosophy, TIGIT, Lung, Kidney cancer, Growth, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.
  • The equity investment and collaboration amendment enable accelerated growth of the companies’ joint development programs that span multiple indications.
  • Additionally, Johanna Mercier, Chief Commercial Officer at Gilead Sciences, will join the Arcus Board, bringing Gilead’s total director designees to three.
  • The amendment also includes governance enhancements enabling streamlined decision-making and reflecting the continued growth of the collaboration.

Gilead and Arcus Announce Amended Collaboration and Equity Investment

Retrieved on: 
Monday, January 29, 2024
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Pancreatic cancer, Patient, Research, MD, Science, Multimedia, Partnership, Cancer, Lung cancer, NSCLC, CD73, Gilead Sciences, Safety, Gastrointestinal cancer, Doctor of Philosophy, TIGIT, Lung, Kidney cancer, Growth, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.
  • The equity investment and collaboration amendment enable accelerated growth of the companies’ joint development programs that span multiple indications.
  • Additionally, Johanna Mercier, Chief Commercial Officer at Gilead Sciences, will join the Arcus Board, bringing Gilead’s total director designees to three.
  • The amendment also includes governance enhancements enabling streamlined decision-making and reflecting the continued growth of the collaboration.

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

Retrieved on: 
Tuesday, January 16, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Death, Patient, ECOG, SCA, OS, Liver disease, ASCO, Survival, History, University, Society, Dassault Group, CD73, Gilead Sciences, Toxicity, Master of Science, Pharmaceutical industry

Arcus Biosciences, Inc. (NYSE:RCUS) today announced promising overall survival data from ARC-8, a Phase 1b study that is being co-developed with Gilead Sciences.

Key Points: 
  • Arcus Biosciences, Inc. (NYSE:RCUS) today announced promising overall survival data from ARC-8, a Phase 1b study that is being co-developed with Gilead Sciences.
  • The results will be presented during the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).
  • Median overall survival (mOS) data for both quemliclustat-based regimens were numerically greater than historical benchmark data for chemotherapy alone, which has shown a mOS of approximately nine months.
  • The efficacy data for the pooled dose-escalation, dose-expansion and randomized arms, as well as the data from the SCA, are summarized below:

Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

Retrieved on: 
Monday, December 11, 2023
PRC2, Partnership, Survival, Bone marrow, Plasma, Lung cancer, Multiple myeloma, Prostate cancer, BCMA, SAN, Half-life, Society, Pharmacokinetics, Serum, Q&A, ASH, Knowledge, CD73, Toxicity, Webcast, Patient, Safety, NK, Pharmaceutical industry

The primary objectives of the trial are safety and determination of the recommended Phase 2 dose (RP2D).

Key Points: 
  • The primary objectives of the trial are safety and determination of the recommended Phase 2 dose (RP2D).
  • As of November 28, 2023, a total of 23 patients with multiple myeloma received doses ranging from 400 mg to 2400 mg once daily.
  • ORIC-533 also demonstrated strong inhibition of soluble CD73 enzymatic activity across all dose levels, highlighting good target engagement, including in the bone marrow.
  • Soluble BCMA levels have been reported to correlate with clinical response on treatment and predict progression free survival of various therapies.

Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

Retrieved on: 
Thursday, December 7, 2023
IO, ESMO, IND, PD-1, Colorectal cancer, SAN, Congress, Therapy, CDTX, CD73, Patient, DFC, Pharmaceutical industry

SAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the presentation of new preclinical data on its novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate (DFC) candidate at the ESMO Immuno-Oncology (IO) Annual Congress. Cidara also presented new preclinical data on CBO421, its first-in-class CD73-targeting DFC. The conference is taking place December 6-8, 2023, virtually and in-person in Geneva, Switzerland.

Key Points: 
  • Cidara also presented new preclinical data on CBO421, its first-in-class CD73-targeting DFC.
  • The conference is taking place December 6-8, 2023, virtually and in-person in Geneva, Switzerland.
  • “We are thrilled to be presenting promising preclinical data on our novel multi-specific DFC in colorectal cancer for the first time at ESMO-IO this year,” said Jeffrey Stein, Ph.D., president and chief executive officer at Cidara.
  • The company plans to file an investigational new drug (IND) application in mid-2024 for CBO421.

Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress

Retrieved on: 
Thursday, November 30, 2023
IO, CDTX, Patient, ESMO, Congress, DFC, CD73, SAN, Therapy

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will present new preclinical data on its novel, dual-acting CD73/PD-1 targeting drug-Fc conjugate (DFC) candidate at the ESMO Immuno-Oncology (IO) Annual Congress.

Key Points: 
  • SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will present new preclinical data on its novel, dual-acting CD73/PD-1 targeting drug-Fc conjugate (DFC) candidate at the ESMO Immuno-Oncology (IO) Annual Congress.
  • Cidara will also present new preclinical data on CBO421, its first-in-class CD73 targeting DFC.
  • The conference is taking place December 6-8, 2023, virtually and in-person in Geneva, Switzerland.
  • Presentation details are summarized below:

Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

Retrieved on: 
Friday, November 17, 2023
Cervical cancer, Progression-free survival, Eastern Time Zone, Hematology, Patient, MD Anderson Cancer Center, Pembrolizumab, Lung cancer, DCR, ORR, Melanoma, Cancer, Nivolumab, Phase, R, PR, Liver disease, NSCLC, CD73, CPI, Vaccine, Pharmaceutical industry, Time in China

ATG-008 (dual mTORC1/2 inhibitor) continued showing strong clinical activities in the Phase II program, with promising efficacy data in cervical cancer patients compared to benchmarks.

Key Points: 
  • ATG-008 (dual mTORC1/2 inhibitor) continued showing strong clinical activities in the Phase II program, with promising efficacy data in cervical cancer patients compared to benchmarks.
  • The event will also include presentations and discussion with three well-known clinical experts from leading medical centers in the U.S. and Australia.
  • Everyone at Antengene has resolute dedication to our mission and these early data affirm that we are delivering."
  • The Chinese session will be held in-person at the Antengene Shanghai Office and virtually at 8:30 AM, November 17, 2023, Beijing Time.